

# Karin Kast

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/732848/publications.pdf>

Version: 2024-02-01

53  
papers

6,598  
citations

186265

28  
h-index

161849

54  
g-index

55  
all docs

55  
docs citations

55  
times ranked

9833  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases. <i>Breast Care</i> , 2022, 17, 153-158.	1.4	1
2	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. <i>European Journal of Cancer</i> , 2022, 160, 100-111.	2.8	12
3	Oral Contraceptive Use in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Absolute Cancer Risks and Benefits. <i>Journal of the National Cancer Institute</i> , 2022, 114, 540-552.	6.3	7
4	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. <i>Cancers</i> , 2022, 14, 521.	3.7	12
5	Oral contraceptive use and ovarian cancer risk for <i>BRCA1/2</i> mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 51.e1-51.e17.	1.3	34
6	Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany – A retrospective cohort study. <i>Cancer Medicine</i> , 2021, 10, 7747-7758.	2.8	7
7	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
8	Breast cancer risk in <i>BRCA1/2</i> mutation carriers and noncarriers under prospective intensified surveillance. <i>International Journal of Cancer</i> , 2020, 146, 999-1009.	5.1	32
9	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
10	Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i> : results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2020, , jmedgenet-2020-107353.	3.2	3
11	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. <i>Cancer</i> , 2020, 126, 4032-4041.	4.1	20
12	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	6.3	106
13	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	5.0	41
14	Patient-Reported Satisfaction after Prophylactic Operations of the Breast. <i>Breast Care</i> , 2019, 14, 217-223.	1.4	7
15	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in <i>BRCA2</i> Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	1.9	148
16	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2019, 56, 574-580.	3.2	34
17	High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 217-228.	2.5	94
18	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	6.3	30

#	ARTICLE	IF	CITATIONS
19	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOctoâ€”GBC 84): A randomised phase III trial. <i>European Journal of Cancer</i> , 2019, 106, 181-192.	2.8	84
20	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	6.4	12
21	Changes in classification of genetic variants in BRCA1 and BRCA2. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 279-280.	1.7	8
22	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky023.	2.9	33
23	Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. <i>BMC Cancer</i> , 2018, 18, 265.	2.6	84
24	Benefits and risks of a percutaneous endoscopic gastrostomy (PEG) for decompression in patients with malignant gastrointestinal obstruction. <i>Supportive Care in Cancer</i> , 2017, 25, 2849-2856.	2.2	24
25	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	7.4	1,898
26	Trastuzumab and survival of patients with metastatic breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 303-312.	1.7	20
27	Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1227-1238.	1.7	18
28	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
29	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
30	BRCA1/2 missense mutations and the value of in-silico analyses. <i>European Journal of Medical Genetics</i> , 2017, 60, 572-577.	1.3	7
31	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). <i>PLoS ONE</i> , 2017, 12, e0186043.	2.5	105
32	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	1.6	152
33	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	2.5	10
34	Prevalence of <i>BRCA1/2</i> germline mutations in 21â€”401 families with breast and ovarian cancer. <i>Journal of Medical Genetics</i> , 2016, 53, 465-471.	3.2	179
35	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88
36	Prevalence of Lynch syndrome in unselected patients with endometrial or ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1299-1303.	1.7	4

#	ARTICLE	IF	CITATIONS
37	RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA. Nature Communications, 2016, 7, 11752.	12.8	127
38	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
39	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
40	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
41	Familial Breast Cancer - Targeted Therapy in Secondary and Tertiary Prevention. Breast Care, 2015, 10, 27-31.	1.4	5
42	Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Research and Treatment, 2015, 150, 621-629.	2.5	157
43	LIFESTYLE und erblicher Brustkrebs. Medizinische Genetik, 2015, 27, 237-243.	0.2	0
44	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
45	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
46	Validation of the Manchester scoring system for predicting <i>BRCA1/2</i> mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. International Journal of Cancer, 2014, 135, 2352-2361.	5.1	29
47	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
48	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
49	Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. BMC Cancer, 2012, 12, 217.	2.6	19
50	Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer. BMC Cancer, 2012, 12, 531.	2.6	12
51	Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nature Genetics, 2010, 42, 410-414.	21.4	638
52	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
53	MLPA screening in the <i>BRCA1</i> gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases. Human Mutation, 2008, 29, 948-958.	2.5	81